Octapharma AG
Seidenstraße 2
Lachen
CH-8853
Tel: 41-55-451-2121
Fax: 41-55-451-2110
Website: http://www.octapharma.com/content/
Email: kbjoernstrup@octapharma.ch
82 articles about Octapharma AG
-
Publication of data from WIL-31 study marks a milestone in improving long-term care for patients with severe von Willebrand disease (VWD)
1/22/2024
Octapharma announced the publication of the results from the clinical study WIL-31, which investigated the efficacy and safety of prophylaxis with wilate®, a von Willebrand factor/factor VIII concentrate, in patients with all types of von Willebrand disease.
-
Octapharma presents new data at ISTH 2023 in an ongoing commitment to improve the lives of people with bleeding disorders
6/6/2023
The most recent developments from Octapharma's Haematology and Critical Care portfolios will be presented at the 31st Congress of the International Society on Thrombosis and Haemostasis on June 24–28, 2023, in Montréal, Canada.
-
Octapharma to present new clinical data and studies at ASH 2022 to demonstrate its continued mission to meet the challenges faced by people with bleeding disorders
12/5/2022
New clinical data from Octapharma's haematology portfolio, including the results of the phase 3 WIL-31 study, will be presented during the Scientific Program at the 64th American Society of Hematology (ASH) Meeting on December 10–13, 2022.
-
Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders
7/4/2022
The latest developments in Octapharma's haematology and critical care portfolios will be presented at the 30th International Society on Thrombosis and Haemostasis Congress on July 9–13, 2022, in London, UK.
-
Octapharma to address unmet needs in von Willebrand disease as a proud sponsor of WFH 2022 World Congress
4/26/2022
As part of its ongoing commitment to the global bleeding disorders community, Octapharma is pleased to be a Gold Sponsor of the upcoming World Federation of Haemophilia 2022 World Congress, taking place from May 8 to 11, 2022.
-
Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
1/19/2022
The virtual symposium held on Wednesday, February 2, 2022, at 18:00 CET, will tell the story of the Rodriguez family and their two sons with haemophilia A as they navigate the challenges of inhibitor management.
-
Octapharma's ongoing dedication to improving the lives of people with haemophilia and von Willebrand disease to be showcased at the ISTH 2021 Congress
7/5/2021
Octapharma announced that new clinical and scientific findings encompassing their Haematology portfolio, including Nuwiq®, wilate®, octanate® and octanine®F, will be presented at the upcoming International Society on Thrombosis and Haemostasis Virtual Congress, taking place on July 17–21, 2021.
-
Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A
2/22/2021
Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis
-
Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq® in Previously Untreated Patients With Severe Haemophilia A
2/18/2021
Octapharma announced that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study” https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623).
-
Akron Biotech Signs Exclusive Global Agreement with Octapharma to Produce Virally Inactivated Human AB Serum Derived from Octaplas® for the Cell Therapy Market
1/20/2021
Akron Biotechnology, LLC, announced it has signed an exclusive global agreement to manufacture virally inactivated Human AB Serum for the cell therapy market using Octaplas®, Octapharma’s pooled, solvent-detergent treated human plasma.
-
Octapharma to Demonstrate Ongoing Commitment to Improving the Long-term Health of People With Haemophilia A at the 14th EAHAD Annual Congress
1/11/2021
Octapharma announced a satellite symposium and poster presentation at the 14th annual congress of the European Association for Haemophilia and Allied Disorders, which will be held virtually from February 3–5, 2021.
-
Positive Results From ProDERM Study of octagam® 10% in Patients With Dermatomyositis Meeting the Primary Endpoint Will Be Presented at ACR Convergence 2020
11/6/2020
Octapharma announces that the final results from the phase III ProDERM study will be presented at the American College of Rheumatology (ACR) Convergence 2020 virtual meeting.
-
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill COVID-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as it assesses the plasma-based treatment in a Phase III study.
-
New Data to Be Presented at the ISTH 2020 Virtual Congress Demonstrating Octapharma’s Commitment to Patients With Bleeding Disorders
7/13/2020
Octapharma announced today that new research findings from its haematology portfolio will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on 12–14 July 2020. The NuProtect study (NCT01712438) investigated the immunogenicity, efficacy and safety of Nuwiq ® (simoctocog alfa) in 108 previously untreated patients with haemophilia A. The final re
-
Final results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga® (NewGam) in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) presented at AAN 2020
5/18/2020
Octapharma has announced that results from the ProCID study were shared for the first time as a poster presentation during the virtual American Academy of Neurology 2020 annual meeting.
-
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
4/6/2020
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
-
CORRECTING and REPLACING Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
4/6/2020
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
-
Octapharma demonstrates commitment to improving haemophilia A treatment at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
2/6/2020
Octapharma had a prominent role as a Sponsor of the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders Congress this week, which takes place in The Hague, The Netherlands, from February 5–7, 2020.
-
Final results from the NuProtect study demonstrating efficacy of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) presented at ASH 2019
12/10/2019
Octapharma has announced that the final results from the NuProtect study, the largest prospective study of a single factor VIII product in true PUPs with severe haemophilia A, were presented in an oral presentation at the American Society of Hematology 2019 Annual Meeting in Orlando, Florida.
-
Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019
12/2/2019
Octapharma has announced that the final results of the NuProtect study will be presented by Dr Ri Liesner as an oral presentation at the 61st Annual Meeting of the American Society of Hematology 2019 in Orlando, Florida.